Membrane-associated enzymes have been found to behave differently qualitatively and quantitatively in terms of activity. These findings were highly debated in the 1970s and many general correlations ...

− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

Two enzymes — ADAMTS13 and DNase 1 — might be key to breaking up blood clots in patients with ischemic stroke, new research is showing. "It's amazing how little we've known about thrombi," said Simon ...

Including biomarkers for non-ADAMTS13 in routine clinical testing could benefit diagnosis and follow-up in patients with immune-mediated thrombotic thrombocytopenic purpura (TTP). Patients with immune ...

The FDA said it has received postmarketing reports of neutralizing antibodies to ADAMTS13, including one death, in patients with congenital thrombotic thrombocytopenic purpura (cTTP) who were treated ...

cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. 1 It is associated with acute events and debilitating chronic symptoms or thrombotic ...

Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...

Takeda is launching an international chart review to better understand long-term treatment of people with congenital thrombotic thrombocytopenic purpura, or cTTP, who received its recombinant ADAMTS13 ...

For reference, ADAMTS13 is a key regulator of blood clotting, preventing excessive clot formation in normal circulation. Its primary function is to cleave vWF, a large protein that helps platelets ...